Post-immunotherapy imaging in lung cancer

G S Shroff; C D Strange; M Altan; B W Carter; J Ahuja; M C B Godoy; M T Truong; I Vlahos

doi:10.1016/j.crad.2021.05.003

Post-immunotherapy imaging in lung cancer

Clin Radiol. 2022 Jan;77(1):44-57. doi: 10.1016/j.crad.2021.05.003. Epub 2021 Jun 5.

Authors

G S Shroff¹, C D Strange², M Altan³, B W Carter², J Ahuja², M C B Godoy², M T Truong², I Vlahos²

Affiliations

¹ The University of Texas MD Anderson Cancer Center, Thoracic Imaging, 1515 Holcombe Blvd. Unit 1478, Houston, TX 77030, USA. Electronic address: gshroff@mdanderson.org.
² The University of Texas MD Anderson Cancer Center, Thoracic Imaging, 1515 Holcombe Blvd. Unit 1478, Houston, TX 77030, USA.
³ The University of Texas MD Anderson Cancer Center, Thoracic/Head and Neck Medical Oncology, 1515 Holcombe Blvd. Unit 0432, Houston, TX 77030, USA.

PMID: 34103147
DOI: 10.1016/j.crad.2021.05.003

Abstract

By boosting the immune system, immunotherapy with immune checkpoint inhibitors (ICIs) has altered the management of patients with various cancers including those with metastatic non-small cell lung cancer (NSCLC). As a result of immune system activation, ICIs are associated with unique response patterns (that are not addressed by traditional response criteria) and inflammatory side effects termed immune-related adverse events. In this article, we will review the role of immunotherapy in cancer treatment, specifically ICIs used in NSCLC treatment, radiological response criteria of immunotherapy, and the imaging spectrum of immune-related adverse events.

Publication types

Review

MeSH terms

Diagnostic Imaging / methods*
Humans
Immunotherapy / methods*
Lung / diagnostic imaging
Lung / immunology
Lung Neoplasms / diagnostic imaging*
Lung Neoplasms / drug therapy*
Lung Neoplasms / immunology